Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
Vancouver, BC – September 7, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the appointment of Doug Williamson to the Company’s Board of Directors(the “Board”).Dr. Williamson will serve…
